Literature DB >> 27184990

Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer.

Jinping Xu1, James Janisse2, Julie J Ruterbusch3, Joel Ager2, Joe Liu4, Margaret Holmes-Rovner5, Kendra L Schwartz2.   

Abstract

PURPOSE: Overtreatment of screen-detected localized prostate cancer (LPC) is an important public health concern, since the survival benefit of aggressive treatment (surgery or radiation) has not been well established. We investigated the survival expectations of patients who had LPC with and without their chosen treatment.
METHODS: A population-based sample of 260 men (132 black, 128 white) 75 years old or younger with newly diagnosed LPC completed a self-administered survey. How long the patients expected to live with their chosen treatment, how long they would expect to live with no treatment, and factors associated with the difference in perceived life expectancy were assessed using multivariable analysis.
RESULTS: Without any treatment, 33% of patients expected that they would live less than 5 years, 41% 5 to 10 years, 21% 10 to 20 years, and 5% more than 20 years. With their chosen treatment, 3% of patients expected to live less than 5 years, 9% 5 to 10 years, 33% 10 to 20 years, and 55% more than 20 years. Treatment chosen, age, general health perception, and perceived cancer seriousness predicted the differences in perceived life expectancy, while race and actual tumor risk did not. After adjustment for other covariates, men who choose surgery or radiation expected greater gain in survival than men who chose watchful waiting or active surveillance.
CONCLUSIONS: Most patients with LPC underestimated their life expectancy without treatment and overestimated the gain in life expectancy with surgery or radiation. These unrealistic expectations may compromise patients' ability to make informed treatment decisions and may contribute to overtreatment of LPC. Primary care physicians, when included in the decision process, should focus on helping patients develop realistic expectations and choices that support their treatment goals.
© 2016 Annals of Family Medicine, Inc.

Entities:  

Keywords:  active surveillance; localized prostate cancer; radiation; shared decision making; surgery; survival expectation; watchful waiting

Mesh:

Year:  2016        PMID: 27184990      PMCID: PMC4868558          DOI: 10.1370/afm.1926

Source DB:  PubMed          Journal:  Ann Fam Med        ISSN: 1544-1709            Impact factor:   5.166


  37 in total

1.  Men's perspectives on selecting their prostate cancer treatment.

Authors:  Jinping Xu; Rhonda K Dailey; Susan Eggly; Anne Victoria Neale; Kendra L Schwartz
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

2.  Less is more: Overdiagnosis and overtreatment: evaluation of what physicians tell their patients about screening harms.

Authors:  Odette Wegwarth; Gerd Gigerenzer
Journal:  JAMA Intern Med       Date:  2013 Dec 9-23       Impact factor: 21.873

3.  Radical prostatectomy versus observation for localized prostate cancer.

Authors:  Timothy J Wilt; Michael K Brawer; Karen M Jones; Michael J Barry; William J Aronson; Steven Fox; Jeffrey R Gingrich; John T Wei; Patricia Gilhooly; B Mayer Grob; Imad Nsouli; Padmini Iyer; Ruben Cartagena; Glenn Snider; Claus Roehrborn; Roohollah Sharifi; William Blank; Parikshit Pandya; Gerald L Andriole; Daniel Culkin; Thomas Wheeler
Journal:  N Engl J Med       Date:  2012-07-19       Impact factor: 91.245

4.  Trends in the treatment of localized prostate cancer using supplemented cancer registry data.

Authors:  Ann S Hamilton; Peter C Albertsen; Terri Kang Johnson; Richard Hoffman; Donna Morrell; Dennis Deapen; David F Penson
Journal:  BJU Int       Date:  2010-08-24       Impact factor: 5.588

5.  Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.

Authors:  Simon P Kim; Cary P Gross; Paul L Nguyen; Marc C Smaldone; Nilay D Shah; R Jeffrey Karnes; R Houston Thompson; Leona C Han; James B Yu; Quoc D Trinh; Jeanette Y Ziegenfuss; Maxine Sun; Jon C Tilburt
Journal:  Med Care       Date:  2014-07       Impact factor: 2.983

6.  Cost implications of the rapid adoption of newer technologies for treating prostate cancer.

Authors:  Paul L Nguyen; Xiangmei Gu; Stuart R Lipsitz; Toni K Choueiri; Wesley W Choi; Yin Lei; Karen E Hoffman; Jim C Hu
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

7.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Viswanath; Hunter Wessells
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391

8.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

Review 9.  Decision aids for people facing health treatment or screening decisions.

Authors:  Dawn Stacey; France Légaré; Nananda F Col; Carol L Bennett; Michael J Barry; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; Richard Thomson; Lyndal Trevena; Julie H C Wu
Journal:  Cochrane Database Syst Rev       Date:  2014-01-28

10.  Patient perspective on watchful waiting/active surveillance for localized prostate cancer.

Authors:  Jinping Xu; Anne Victoria Neale; Rhonda K Dailey; Susan Eggly; Kendra L Schwartz
Journal:  J Am Board Fam Med       Date:  2012 Nov-Dec       Impact factor: 2.657

View more
  8 in total

1.  askMUSIC: Leveraging a Clinical Registry to Develop a New Machine Learning Model to Inform Patients of Prostate Cancer Treatments Chosen by Similar Men.

Authors:  Gregory B Auffenberg; Khurshid R Ghani; Shreyas Ramani; Etiowo Usoro; Brian Denton; Craig Rogers; Benjamin Stockton; David C Miller; Karandeep Singh
Journal:  Eur Urol       Date:  2018-10-11       Impact factor: 20.096

2.  Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review.

Authors:  Netty Kinsella; Pär Stattin; Declan Cahill; Christian Brown; Anna Bill-Axelson; Ola Bratt; Sigrid Carlsson; Mieke Van Hemelrijck
Journal:  Eur Urol       Date:  2018-03-26       Impact factor: 20.096

3.  How Men with Prostate Cancer Choose Specialists: A Qualitative Study.

Authors:  Tammy Jiang; Christian H Stillson; Craig Evan Pollack; Linda Crossette; Michelle Ross; Archana Radhakrishnan; David Grande
Journal:  J Am Board Fam Med       Date:  2017 Mar-Apr       Impact factor: 2.657

4.  Active surveillance for low-risk localized prostate cancer: what do men and their partners think?

Authors:  Arun Mallapareddi; Julie Ruterbusch; Elyse Reamer; Susan Eggly; Jinping Xu
Journal:  Fam Pract       Date:  2016-12-29       Impact factor: 2.267

5.  Influence of Men's Personality and Social Support on Treatment Decision-Making for Localized Prostate Cancer.

Authors:  Elyse Reamer; Felix Yang; Margaret Holmes-Rovner; Joe Liu; Jinping Xu
Journal:  Biomed Res Int       Date:  2017-07-12       Impact factor: 3.411

6.  Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study.

Authors:  Oskar Bergengren; Hans Garmo; Ola Bratt; Lars Holmberg; Eva Johansson; Anna Bill-Axelson
Journal:  BMJ Open       Date:  2019-12-23       Impact factor: 2.692

7.  Five-year follow-up study of a population-based prospective cohort of men with low-risk prostate cancer: the treatment options in prostate cancer study (TOPCS): study protocol.

Authors:  Jinping Xu; Michael Goodman; James Janisse; Michael L Cher; Cathryn Hufford Bock
Journal:  BMJ Open       Date:  2022-02-21       Impact factor: 2.692

8.  Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making.

Authors:  Nynikka R Palmer; Steven E Gregorich; Jennifer Livaudais-Toman; Jane Jih; Celia P Kaplan
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.